2. Immunology/Inflammation
  3. CD19
  4. Blinatumomab

Blinatumomab  (Synonyms: Anatumomab; bscCD19xCD3; AMG-103; MEDI-538; MT-103; BLINCYTO)

Cat. No.: HY-P9963 Purity: 97.33%
COA
SDS
Technical Support

Blinatumomab (Anatumomab) is a bispecific monoclonal antibody with two binding sites, one for CD3E on T cells and one for CD19 on B cells. Blinatumomab can be used in research for acute lymphoblastic leukemia.

For research use only. We do not sell to patients.

CAS No. : 853426-35-4

Size Price Stock Quantity
100 μg In-stock
500 μg In-stock
1 mg In-stock
5 mg In-stock
10 mg In-stock
50 mg   Get quote  
100 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Blinatumomab Featured Recommendations:

Blinatumomab Related Antibodies

Top Publications Citing Use of Products

1 Publications Citing Use of MCE Blinatumomab

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Blinatumomab (Anatumomab) is a bispecific monoclonal antibody with two binding sites, one for CD3E on T cells and one for CD19 on B cells. Blinatumomab can be used in research for acute lymphoblastic leukemia[1][2][3][4].

IC50 & Target

CD19 & CD3E
In Vivo

Blinatumomab (0.01-1 μg, i.v. once daily for 5 days) extended the survival of mice in a dose-dependent manner in a leukemic nonobese diabetic SCID mouse model[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: leukemic nonobese diabetic SCID mouse model (20 days old)[2]
Dosage: 0.01-1 μg
Administration: Intravenous injection (i.v.), once daily for 5 days
Result: Caused none of the animals developed detectable tumors and survived inoculation of NALM-6 cells at cumulative doses of 5 or 0.5 μg for the entire observation period of 76 days. Cumulative doses of 0.05 and 0.005 μg were not effective in preventing tumor growth.
Clinical Trial
Gene ID

12479  [NCBI] & 916  [NCBI]

Accession
Application

ELISA, FACS, Functional assay
Conjugated

Unconjugated
Reconsititution

The product can be reconstituted/diluted with sterile PBS or saline.
Molecular Weight

54.09 kDa

CAS No.
Appearance

Liquid

Color

Colorless to light yellow

SMILES

[Blinatumomab]
Shipping

Shipping with dry ice.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Format
  • (scFv-kappa-heavy)-(scFv-heavy-kappa)
Biological Activity
  • Loaded Blinatumomab on CM5 Chip, can bind CD19 Protein, Human (CHO, Fc, HY-P7333) with an affinity constant of 11.02E-9 M as determined in SPR assay.
Purity & Documentation

Purity: 98.78%

SDS (251 KB)

COA (232 KB) SDS-PAGE (92 KB) SEC-HPLC (197 KB)

Inhibitory Antibodies User Guide (602 KB)
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Blinatumomab Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Blinatumomab853426-35-4Anatumomab bscCD19xCD3 AMG-103 MEDI-538 MT-103 BLINCYTOAMG103AMG 103AMG-103MEDI538MEDI 538MEDI-538MT103MT 103MT-103CD19bispecific monoclonal antibodyacute lymphoblastic leukemiaInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Blinatumomab
Cat. No.:
HY-P9963
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

English - EN (251 KB) Français - FR (251 KB) Deutsch - DE (251 KB) Norwegian - NO (251 KB) Español - ES (251 KB) Swedish - SV (251 KB) Italian - IT (251 KB) Portuguese - PT (251 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.